79 The weight-loss mechanism, rather than a direct drug effect, may be the key driver
Call us at 08068507599 to know more or simple avail a 1-on-1 consultation with our highly experienced in-house specialist, Dr
potential long-term risks include pancreatitis, gallbladder disease, lean muscle loss, and early worsening of diabetic retinopathy, though no confirmed causal links exist beyond 48 weeks of data
By application analysis In 2024, the type 2 diabetes mellitus segment led the GLP-1 receptor agonist market due to the high incidence of the disease and the major efficacy of these drugs in controlling blood sugar levels and encouraging weight loss, contributing majorly to the expansion of the type 2 diabetes mellitus segment
Over the years, people have turned to extreme and unlikely interventions to try to lose weight, from jaw wiring, laxatives, and vagotomies to lap band operations and fen-phen, a miracle diet drug that was ultimately recalled
2019;139(25):e1082143